Cure8 research brief
This registry study offers real-world data on ozanimod effectiveness, persistence, and safety in UC patients, which can help patients and clinicians set expectations beyond clinical trial settings.
Adults with ulcerative colitis; clinicians prescribing ozanimod or other small-molecule therapies; researchers studying real-world IBD treatment outcomes.
This analysis used the Dutch ICC Registry to follow 42 patients (age ≥16) who started ozanimod in routine care. Among those with clinically active disease at baseline, 28.6% achieved clinical remission at week 24 using a conservative imputation method (mNRI); observed-case rates were higher (54.5%).
Treatment persistence was limited for many patients: 27/42 discontinued with a median treatment duration of 25 weeks. No serious adverse events were reported in this cohort. The study provides real-world effectiveness and safety data but reflects a small, selected patient group and uses registry-observed outcomes rather than randomized comparison.
Results are reported through week 104 but include missing-data handling (mNRI) and observed-case analyses.
Prospective observational data from a national registry; small sample size and selected population limit generalizability. Reported as posted content on Research Square with abstract-level depth.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study provides real-world data on ozanimod effectiveness, safety, and how prior biologic exposure (notably vedolizumab) may affect treatment persistence—information relevant for treatment planning in UC.
Patients with UC who fail both anti-TNF and JAK inhibitor therapies have limited options. This report suggests tacrolimus can be used as a short-term bridge or in combination to reach another maintenance drug, with many...
S1P receptor modulators are an emerging oral class of advanced therapy for moderate-to-severe ulcerative colitis; a systematic review that pools multiple RCTs helps clarify how effective and safe the class appears to be...
